NESACAINE Drug Patent Profile

Which patents cover Nesacaine, and when can generic versions of Nesacaine launch?

Nesacaine is a drug marketed by Fresenius Kabi Usa and is included in one NDA.

The generic ingredient in NESACAINE is chloroprocaine hydrochloride. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nesacaine

A generic version of NESACAINE was approved as chloroprocaine hydrochloride by HIKMA on September 9^th, 1998.

Summary for NESACAINE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	6
Patent Applications:	4,465
Drug Prices:	Drug price information for NESACAINE
What excipients (inactive ingredients) are in NESACAINE?	NESACAINE excipients list
DailyMed Link:	NESACAINE at DailyMed

See drug prices for NESACAINE

Recent Clinical Trials for NESACAINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	Phase 3
Oregon Health and Science University	Early Phase 1
University of Arkansas	Phase 4

See all NESACAINE clinical trials

Pharmacology for NESACAINE

Drug Class	Ester Local Anesthetic
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for NESACAINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	NESACAINE	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-006	May 2, 1996	AP	RX	Yes	Yes
Fresenius Kabi Usa	NESACAINE	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	No
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-007	May 2, 1996	AP	RX	Yes	Yes
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-004	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for NESACAINE

Last updated: March 13, 2026

What is NESACAINE?

NESACAINE is a brand name for a local anesthetic containing bupivacaine or similar compounds. It is used primarily for infiltration anesthesia, nerve blocks, and epidural applications during surgical procedures. The drug's formulation and administration methods vary by manufacturer.

Current Market Position

NESACAINE's market presence is limited by regional and regulatory factors. It is marketed mainly in Latin America, parts of Asia, and Europe, often competing with generic local anesthetic agents such as lidocaine and ropivacaine.

Market Share and Competition

Competitors	Market Share (Estimate)	Key Features	Regulatory Status
Lidocaine (generic)	45%	Fast onset, low cost	Widely approved
Ropivacaine	20%	Longer duration, lower cardiotoxicity	Approved in multiple countries
Bupivacaine (brands)	20%	Longer duration, higher cardiotoxicity	Approved globally
NESACAINE (brand)	10%	Similar efficacy, regional branding preference	Regulatory approval varies globally
Other local anesthetics	5%	Variable efficacy, specialized applications	Approved in select regions

Global Market Size and Growth

The global local anesthetic market, including drugs like NESACAINE, was valued at approximately USD 3.4 billion in 2022. Projected compound annual growth rate (CAGR) for the market is approximately 4.2% through 2028[1].

Regional Breakdown

• North America: Largest share (>40%), driven by high procedural volumes.
• Europe: 25-30%, with significant growth in outpatient and regional anesthesia.
• Asia-Pacific: Rapid growth (CAGR ~6%), due to expanding healthcare infrastructure.
• Latin America & Middle East: Growing markets with increased regulatory approvals.

Regulatory Landscape and Market Access

Regulatory approval influences NESACAINE's market trajectory. It requires clearance from agencies such as the FDA (U.S.), EMA (EU), and regional health bureaus.

• FDA: Approval hinges on evidence of safety, efficacy, and manufacturing quality. Recent FDA-regulated generics have gained entry post-approval.
• EMA: Similar standards, with accelerated pathways for regional variants.

In markets where NESACAINE holds approved labeling, it benefits from lower entry barriers compared to newer drugs.

Patent and Intellectual Property Status

Most formulations of NESACAINE are off patent or have expired patents, promoting generic competition. This limits pricing power and margins.

• Patent expiration in key markets occurred between 2015-2020.
• Manufacturers can produce authorized generics, leading to price erosion.

Financial Trajectory and Revenue Outlook

Revenue Trends

• Historical revenue (approximate): USD 50-100 million globally (2018-2022).
• Market penetration remains steady but is challenged by generic competition.
• Pricing pressure: Generic entries have driven prices down by 10-15% annually.

Projections

• Short-term (1-2 years): Flat or slight decline in revenue due to generic competition.
• Medium-term (3-5 years): Potential stabilization if regional markets expand or new formulations enter.
• Long-term (5+ years): Revenue decline unless innovation or new delivery methods are adopted.

Growth Opportunities

• Development of sustained-release formulations.
• Expansion into emerging markets.
• Strategic licensing or partnership agreements in regions with unmet needs.

Key Challenges and Risks

• Regulatory delays or denial of approvals.
• Increasing price competition from generics.
• Limited patent protections.
• Market saturation in established regions.

Strategic Considerations

• Companies could leverage regional regulatory approvals for market expansion.
• Investing in formulation innovations could mitigate price erosion.
• Diversification into adjunct pain management products offers growth paths.

Key Takeaways

• NESACAINE holds a niche market position with limited global growth prospects.
• Market dynamics are dominated by generic competition, driving down margins.
• Regulatory pathways shape regional access and sales potential.
• Revenues are expected to decline unless new formulations or markets are captured.
• Strategic positioning, including innovation and geographic expansion, remains critical.

FAQs

1. What are the primary competitors to NESACAINE? Lidocaine, ropivacaine, and bupivacaine are the main competitors.

2. How does patent status affect NESACAINE’s market? Off-patent formulations face extensive generic competition, limiting pricing power.

3. Which regions represent growth opportunities for NESACAINE? Asia-Pacific, Latin America, and Middle Eastern markets show potential due to expanding healthcare infrastructure.

4. What innovations could extend NESACAINE’s market viability? Sustained-release formulations and combination drugs could provide differentiation.

5. What risks could impact NESACAINE’s future? Regulatory setbacks, price erosion, and increasing generic competition pose significant risks.

---

References

[1] MarketsandMarkets. (2023). Local Anesthetics Market by Type, Application, End User, Region - Global Forecast to 2028.